The Prostate

Currently, prostate‐specific membrane antigen‐radioligand therapy (PSMA‐RLT) is considered a last‐line treatment option in advanced castration‐resistant prostate cancer. Despite these patients' poor prognosis, accurate estimation of their overall survival (OS) is essential to determine whether benefits exist from the treatment and whether the loss of valuable time and unnecessary side effects can be avoided. The aim of the present study is to evaluate whether various biochemical markers can predict OS in men undergoing PSMA‐RLT and whether the changes assessed after PSMA‐RLT correlate with the OS.

[1]  W. Xue,et al.  Neuroendocrine differentiation markers guide treatment sequence selection in metastatic castration‐resistant prostate cancer , 2019, The Prostate.

[2]  B. Billah,et al.  Clinical Outcomes of 177Lu-PSMA Radioligand Therapy in Earlier and Later Phases of Metastatic Castration-Resistant Prostate Cancer Grouped by Previous Taxane Chemotherapy , 2019, The Journal of Nuclear Medicine.

[3]  U. Haberkorn,et al.  Targeting prostate cancer: Prostate‐specific membrane antigen based diagnosis and therapy , 2019, Medicinal research reviews.

[4]  G. Feldmann,et al.  Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  Yongsheng Song,et al.  Prognostic value of serum alkaline phosphatase in the survival of prostate cancer: evidence from a meta-analysis , 2018, Cancer management and research.

[6]  G. Song,et al.  Prognostic role of chromogranin A in castration-resistant prostate cancer: a meta-analysis , 2018, Asian journal of andrology.

[7]  O. Sartor,et al.  Laboratory-Based Biomarkers and Liver Metastases in Metastatic Castration-Resistant Prostate Cancer. , 2018, The oncologist.

[8]  M. Essler,et al.  Predictive Factors of Response and Overall Survival in Patients with Castration-Resistant Metastatic Prostate Cancer Undergoing 177Lu-PSMA Therapy , 2018, The Journal of Nuclear Medicine.

[9]  Hossein Jadvar,et al.  PSMA Theranostics: Current Status and Future Directions , 2018, Molecular imaging.

[10]  D. Murphy,et al.  [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. , 2018, The Lancet. Oncology.

[11]  K. Rahbar,et al.  Lutetium-177-PSMA-Radioligandentherapie , 2018, Der Urologe.

[12]  R. Mathijssen,et al.  Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel , 2017, Oncotarget.

[13]  R. Fimmers,et al.  Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy , 2017, Oncotarget.

[14]  K. Rahbar,et al.  177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  Rolf Fimmers,et al.  Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617 , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  G. Feldmann,et al.  The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  R. Fimmers,et al.  Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride , 2017, Oncotarget.

[18]  R. Fimmers,et al.  Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617 , 2017, The Journal of Nuclear Medicine.

[19]  W. Brenner,et al.  German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients , 2017, Journal of Nuclear Medicine.

[20]  R. Baum,et al.  PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013 , 2016, The Journal of Nuclear Medicine.

[21]  Oliver Sartor,et al.  Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  K. Rahbar,et al.  Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer , 2016, Clinical nuclear medicine.

[23]  J. Ruf,et al.  Therapie mit 177Lu-PSMA-617, Dosimetrie und Nachsorge beim metastasierten kastrationsresistenten Prostatakarzinom , 2016, Nuklearmedizin.

[24]  R. Fimmers,et al.  Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer , 2016, Oncotarget.

[25]  Tim Holland-Letz,et al.  The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions , 2015, The Journal of Nuclear Medicine.

[26]  N. Corcoran,et al.  Bone Turnover Markers and Prostate Cancer: Not Just a Measure of Bone Disease? , 2015, European urology.

[27]  K. Rahbar,et al.  Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study , 2015, EJNMMI Research.

[28]  S. Barni,et al.  Prognostic role of lactate dehydrogenase in solid tumors: A systematic review and meta-analysis of 76 studies , 2015, Acta oncologica.

[29]  U. Haberkorn,et al.  Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer , 2015, The Journal of Nuclear Medicine.

[30]  R. Montironi,et al.  Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises. , 2014, Journal of biological regulators and homeostatic agents.

[31]  M. Morris,et al.  Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  A. Armstrong,et al.  Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. , 2013, Journal of the National Cancer Institute.

[33]  U. Haberkorn,et al.  Synthesis of Peptide Radiopharmaceuticals for the Therapy and Diagnosis of Tumor Diseases , 2013, Molecules.

[34]  L. Trojan,et al.  Gastrin‐releasing peptide: Predictor of castration‐resistant prostate cancer? , 2011, The Prostate.

[35]  I. Tannock,et al.  Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer , 2009, Clinical Cancer Research.

[36]  P. Verhagen.  Predicting the future in castration-resistant prostate cancer. , 2009, The Lancet. Oncology.

[37]  Xiaoyu Jia,et al.  Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. , 2009, The Lancet. Oncology.

[38]  H. Fuse,et al.  Neuroendocrine differentiation in the progression of prostate cancer , 2009, International journal of urology : official journal of the Japanese Urological Association.

[39]  Zhenghong Lee,et al.  Targeted treatment of prostate cancer , 2007, Journal of cellular biochemistry.

[40]  F. Saad,et al.  Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer. , 2007, Urology.

[41]  G. Sauter,et al.  Prostate‐specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique , 2007, Histopathology.

[42]  R. Coleman.  Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity , 2006, Clinical Cancer Research.

[43]  L. Collette,et al.  Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials. , 2006, European journal of cancer.

[44]  K. Akakura,et al.  Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients. , 2005, European urology.

[45]  J. Pinski,et al.  Prostate cancer metastases to bone: pathophysiology, pain management, and the promise of targeted therapy. , 2005, European journal of cancer.

[46]  L. Dogliotti,et al.  Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. , 2005, Endocrine-related cancer.

[47]  C. Fuller,et al.  Early prostate‐specific antigen (PSA) kinetics following prostate carcinoma radiotherapy , 2004, Cancer.

[48]  W. Heston,et al.  Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer , 2004, Journal of cellular biochemistry.

[49]  M. Sabatino,et al.  Analysis of biochemical bone markers as prognostic factors for survival in patients with hormone-resistant prostate cancer and bone metastases. , 2004, Urology.

[50]  J. Bowie,et al.  A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. , 2003, Molecular biology of the cell.

[51]  M. Yashi,et al.  Elevated serum progastrin‐releasing peptide (31–98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer , 2003, The Prostate.

[52]  M. Yashi,et al.  Serum pro-gastrin-releasing peptide (31-98) in prostatic diseases. , 2003, Urology.

[53]  Kevin Regan,et al.  Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  M. Resnick,et al.  Skeletal fractures negatively correlate with overall survival in men with prostate cancer. , 2002, The Journal of urology.

[55]  Y. Fujiuchi,et al.  Serum pro-gastrin-releasing peptide (31-98) in benign prostatic hyperplasia and prostatic carcinoma. , 2002, Urology.

[56]  H. Nanjo,et al.  Elevated serum progastrin‐releasing peptide (31–98) in metastatic and androgen‐independent prostate cancer patients * , 2002, The Prostate.

[57]  A. Semjonow,et al.  The rise and fall of PSA: clinical implications of prostate specific antigen kinetics , 2002, Urological Research.

[58]  A. Pecking,et al.  Serum chromogranin‐A in advanced prostate cancer , 2001, BJU international.

[59]  G. Andriole,et al.  The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma , 2000, Cancer.

[60]  L. Dogliotti,et al.  Circulating neuroendocrine markers in patients with prostate carcinoma , 2000, Cancer.

[61]  P. Abrahamsson.  Neuroendocrine cells in tumour growth of the prostate. , 1999, Endocrine-related cancer.

[62]  P. Schellhammer,et al.  Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. , 1996, Urology.

[63]  P. di Sant'Agnese,et al.  Neuroendocrine differentiation in prostatic malignancy , 1996, Cancer.

[64]  P. di Sant'Agnese,et al.  Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate. , 1996, Urology.

[65]  O. Cussenot,et al.  Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. , 1996, The Journal of urology.

[66]  M. Assadi,et al.  The Iranian Society of Nuclear Medicine practical guideline on radioligand therapy in metastatic castration-resistant prostate cancer using 177Lu-PSMA , 2018 .

[67]  M Essler,et al.  PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[68]  C. Cordon-Cardo,et al.  Prostate-specific membrane antigen expression in normal and malignant human tissues. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.